<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Infect. Dis</journal-id>
      <journal-title-group>
        <journal-title>BMC Infectious Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2334</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25041573</article-id>
      <article-id pub-id-type="pmc">4223471</article-id>
      <article-id pub-id-type="publisher-id">1471-2334-14-404</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2334-14-404</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case report: failure under azithromycin treatment in a case of bacteremia due to <italic>Salmonella enterica</italic> Paratyphi A</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Kobayashi</surname>
            <given-names>Tetsuro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tootsieroll-29@umin.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Hayakawa</surname>
            <given-names>Kayoko</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>kayokohayakawa@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Mawatari</surname>
            <given-names>Momoko</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mawatamo@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Mezaki</surname>
            <given-names>Kazuhisa</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>kmezaki@hosp.ncgm.go.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Takeshita</surname>
            <given-names>Nozomi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>nozomitake@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Kutsuna</surname>
            <given-names>Satoshi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>linezolid@mac.com</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Fujiya</surname>
            <given-names>Yoshihiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ilvtkfm@yahoo.co.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Kanagawa</surname>
            <given-names>Shuzo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>shuzokanagawa@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Ohmagari</surname>
            <given-names>Norio</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>lukenorioom@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Kato</surname>
            <given-names>Yasuyuki</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ykato@hosp.ncgm.go.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A11">
          <name>
            <surname>Morita</surname>
            <given-names>Masatomo</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>mmorita@nih.go.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku Toyama 1-21-1, 162-8655 Tokyo, Japan</aff>
      <aff id="I2"><label>2</label>Microbiology Laboratory, National Center for Global Health and Medicine, Shinjuku-ku Toyama 1-21-1, 162-8655 Tokyo, Japan</aff>
      <aff id="I3"><label>3</label>National Institute of Infectious Diseases, Shinjuku-ku Toyama 1-23-1, Tokyo, Japan</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <fpage>404</fpage>
      <lpage>404</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>3</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Kobayashi et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Kobayashi et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2334/14/404"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Limited information is available regarding the clinical efficacy of azithromycin for the treatment of enteric fever due to fluoroquinolone-resistant <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi among travelers returning to their home countries.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report a case of a 52-year-old Japanese man who returned from India, who developed a fever of 39&#xB0;C with no accompanying symptoms 10&#xA0;days after returning to Japan from a 1-month business trip to Delhi, India. His blood culture results were positive for <italic>Salmonella</italic> Paratyphi A. He was treated with 14&#xA0;days of ceftriaxone, after which he remained afebrile for 18&#xA0;days before his body temperature again rose to 39&#xB0;C with no apparent symptoms. He was then empirically given 500&#xA0;mg of azithromycin, but experienced clinical and microbiological failure of azithromycin treatment for enteric fever due to <italic>Salmonella</italic> Paratyphi A. However, the minimum inhibitory concentration (MIC) of azithromycin was not elevated (8&#xA0;mg/L). He was again given ceftriaxone for 14&#xA0;days with no signs of recurrence during the follow-up.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>There are limited data available for the treatment of enteric fever using azithromycin in travelers from developed countries who are not immune to the disease, and thus, careful follow-up is necessary. In our case, the low azithromycin dose might have contributed the treatment failure. Additional clinical data are needed to determine the rate of success, MIC, and contributing factors for success and/or failure of azithromycin treatment for both <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi infections.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd><italic>Salmonella</italic> Paratyphi</kwd>
        <kwd>Enteric fever</kwd>
        <kwd>Azithromycin</kwd>
        <kwd>Treatment failure</kwd>
        <kwd>Returned traveler</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p><italic>Salmonella enterica</italic> Typhi and <italic>Salmonella enterica</italic> Paratyphi A, B, and C are the causative pathogens of enteric fever in tropical and subtropical countries such as southern and southeast Asia and Africa [<xref ref-type="bibr" rid="B1">1</xref>], and fluoroquinolone-resistant strains of <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi A have recently emerged in these countries [<xref ref-type="bibr" rid="B2">2</xref>]. In developed countries, these strains cause enteric fever in travelers returning from the endemic areas [<xref ref-type="bibr" rid="B3">3</xref>]. Azithromycin and the third-generation cephalosporins (e.g., ceftriaxone) are the drugs of choice for treatment of fluoroquinolone-resistant <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi [<xref ref-type="bibr" rid="B4">4</xref>]. However, the azithromycin breakpoints for <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi A have not been defined by the Clinical and Laboratory Standard Institutions (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. The number of studies regarding the clinical efficacy of azithromycin for the treatment of enteric fever is still limited, and to our knowledge, all of them were conducted in endemic areas [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. Here, we report a case of azithromycin treatment failure in a Japanese man with <italic>Salmonella</italic> Paratyphi A infection who returned from travel.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 52-year-old Japanese man developed a fever of 39&#xB0;C with no accompanying symptoms 10&#xA0;days after returning to Japan from a 1-month business trip to Delhi, India. He presented to a local clinic 5&#xA0;days after the fever developed. Blood cultures grew with Gram-negative rods (GNR) after 3&#xA0;days, which were subsequently identified as <italic>Salmonella</italic> Paratyphi A with unknown antibiotic susceptibility. The patient was transferred to our hospital to complete his 14-d therapy with ceftriaxone (2&#xA0;g daily). He was afebrile for 18&#xA0;days following the completion of the antibiotic therapy, after which his body temperature rose to 39&#xB0;C with no apparent symptoms. He presented to our hospital on Day 3 of the second fever. A blood culture was performed, and the patient was empirically treated with oral azithromycin (500&#xA0;mg daily) owing to a suspected relapse of enteric fever. The patient was compliant with the oral antibiotic regimen. As the blood culture results showed GNR growth in 2&#xA0;days, he was readmitted to our hospital for further treatment. We continued azithromycin treatment under direct observation by the medical staff for a total of 7&#xA0;days. GNR was again identified as <italic>Salmonella</italic> Paratyphi A, which was found to be susceptible to ceftriaxone (minimum inhibitory concentration [MIC], 0.12&#xA0;mg/L), resistant to nalidixic acid, and showed decreased susceptibility to ciprofloxacin (MIC, 0.5&#xA0;mg/L). The MIC&#x2019;s for azithromycin were 8&#xA0;mg/L and 16&#xA0;mg/L, as determined in a reference laboratory using the E-test (Biomerieux Co. Ltd., Tokyo, Japan) and broth micro dilution (BMD), respectively.</p>
      <p>Despite the uninterrupted 7&#xA0;days of oral azithromycin treatment under direct observation, the patient remained febrile until the final day of the regimen. Another blood culture was performed, and the treatment was switched to ceftriaxone because of suspected azithromycin treatment failure. The blood culture showed GNR growth, which was again identified as <italic>Salmonella</italic> Paratyphi A with the same MICs for ceftriaxone, ciprofloxacin, and azithromycin as the initial culture results. Fluorodeoxyglucose positron emission tomography (FDG- PET) showed slightly thickened intestinal wall of the colon. However, no other inflammatory focuses suggesting deep-seeded infection, such as abscesses and aortitis, were detected. The abdominal ultrasound showed no intra-abdominal abscess on the thickened intestinal wall. The patient defervesced on Day 3 of ceftriaxone, and the result of the follow-up blood culture performed on Day 4 of ceftriaxone therapy yielded no growth. After completion of 14&#xA0;days of antibiotic treatment, the patient was discharged with no signs of recurrence during the follow-up.</p>
      <sec>
        <title>Discussion</title>
        <p>Enteric fever due to nalidixic acid-resistant <italic>Salmonella</italic> Typhi and/or <italic>Salmonella</italic> Paratyphi A is generally treated with ceftriaxone or azithromycin [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] with previous reports demonstrating the efficacy of azithromycin in the treatment of enteric fever [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Moreover, the probability of recurrence is&#x2009;&lt;&#x2009;3% when treated with azithromycin compared to 3&#x2013;6% when treated with ceftriaxone. Therefore, treatment with azithromycin may be preferred for quinolone-resistant <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi A [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. However, data are currently only available for endemic regions of enteric fever where immunity to the disease may contribute to the high success rates.</p>
        <p>To the best of our knowledge, there has only been fewcase reports of treatment failure with azithromycin for <italic>Salmonella</italic> Paratyphi A. In one report, the MIC for azithromycin was&#x2009;&gt;&#x2009;64&#xA0;mg/L, which was assumed to be azithromycin-resistant; however, the exact mechanism of resistance has not been defined [<xref ref-type="bibr" rid="B15">15</xref>]. In another report, a case of recurrent, multifocal Salmonella enterica serotype Paratyphi A breast abscesses was presented which relapsed despite surgery and multiple courses of antibiotics, including co-trimoxazole and azithromycin [<xref ref-type="bibr" rid="B16">16</xref>]. Although the bioavailability of oral azithromycin was reported to be approximately 37%, which is lower than that for fluoroquinolones, it has been suggested that the intracellular concentration of azithromycin is 50&#x2013;100 times greater than that in serum and that the bactericidal effect remains stable regardless of a high MIC [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. The recent CLSI guidelines and the EUCAST criteria do not specify the MIC for azithromycin when treating <italic>Salmonella</italic> Typhi or <italic>Salmonella</italic> Paratyphi A [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. However, the EUCAST states that the wild-type isolates of <italic>Salmonella</italic> Typhi have an MIC&#x2009;&#x2264;&#x2009;16&#xA0;mg/L [<xref ref-type="bibr" rid="B6">6</xref>]. In a study conducted in India, the MIC distributions for <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi A ranged from 0.0612 to 64&#xA0;mg/L and from 1 to 32&#xA0;mg/L, respectively, and the MIC90 values were 24&#xA0;mg/L for both serovars [<xref ref-type="bibr" rid="B19">19</xref>]. Recent report on MIC distribution of typhoidal Salmonella isolates of returned travelers showed that azithromycin MICs were 2&#x2013;256&#xA0;&#x3BC;g/mL among the 354 isolates, and a minority of the S. Paratyphi A isolates showed an MIC&#x2009;&#x2264;&#x2009;8&#xA0;mg/L [<xref ref-type="bibr" rid="B20">20</xref>].</p>
        <p>In the present case, we experienced clinical and microbiological treatment failure with azithromycin for enteric fever due to <italic>Salmonella</italic> Paratyphi A despite the fact that the MIC for azithromycin was not elevated (8&#xA0;mg/L by E-test and 16&#xA0;mg/L by BMD). Previous studies evaluated the efficacy of azithromycin therapy used various regimens as summarized in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>. Most of the dosages used ranged from 10&#xA0;mg/kg to 20&#xA0;mg/kg. A review published in 2005 recommends 8&#x2013;10&#xA0;mg&#x2009;&#xB7;&#x2009;kg<sup>-1</sup>&#x2009;&#xB7;&#x2009;dose<sup>-1</sup> azithromycin for enteric fever caused by either <italic>Salmonella</italic> Typhi or <italic>Salmonella</italic> Paratyphi A [<xref ref-type="bibr" rid="B12">12</xref>]. Owing to the patient&#x2019;s weight (80&#xA0;kg) at the time of admission, 500&#xA0;mg of azithromycin [<xref ref-type="bibr" rid="B13">13</xref>], which was 6.25&#xA0;mg/kg, might have been an inadequate dose when compared to previously recommended doses. Further studies are necessary in terms of optimal route of administration, and appropriate dose and duration especially among returned travelers who are not immune to typhoid.</p>
        <table-wrap position="float" id="T1">
          <label>Table 1</label>
          <caption>
            <p>
              <bold>Reported efficacy of azithromycin for treatment of </bold>
              <bold>
<italic>Salmonella </italic>
</bold>
              <bold>Typhi and </bold>
              <bold>
<italic>Salmonella </italic>
</bold>
              <bold>Paratyphi</bold>
            </p>
          </caption>
          <table frame="hsides" rules="groups" border="1">
            <colgroup>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
              <col align="left"/>
            </colgroup>
            <thead valign="top">
              <tr>
                <th align="left">
                  <bold>Author, year</bold>
                </th>
                <th align="left">
                  <bold>Country</bold>
                </th>
                <th align="left">
                  <bold>Patients population</bold>
                </th>
                <th align="left">
                  <bold>Azithromycin dose</bold>
                </th>
                <th align="left">
                  <bold>Body weights of patients (kg)</bold>
                </th>
                <th align="left">
                  <bold>Route of administration</bold>
                </th>
                <th align="left">
                  <bold>Efficacy</bold>
                </th>
                <th align="left">
                  <bold>MIC of isolates, g/L*</bold>
                </th>
                <th align="left">
                  <bold>References</bold>
                </th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td align="left" valign="top">Girgis, 1999<hr/></td>
                <td align="left" valign="top">Egypt<hr/></td>
                <td align="left" valign="top">n&#x2009;=&#x2009;36, mean age (range): 19.6 (18&#x2013;30)<hr/></td>
                <td align="left" valign="top">1&#xA0;g/day on the first day, followed by 500&#xA0;mg/day on the next 6&#xA0;days<hr/></td>
                <td align="left" valign="top">NA<hr/></td>
                <td align="left" valign="top">Oral<hr/></td>
                <td align="left" valign="top">Clinical cure rate: 100%<hr/></td>
                <td align="left" valign="top">BMD, MIC*<sub>90</sub> (range): 8 (4&#x2013;16)<hr/></td>
                <td align="left" valign="top">[<xref ref-type="bibr" rid="B9">9</xref>]<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="top">Butler, 1999<hr/></td>
                <td align="left" valign="top">India<hr/></td>
                <td align="left" valign="top">n&#x2009;=&#x2009;42, mean age (range): 26.2 (17&#x2013;53)<hr/></td>
                <td align="left" valign="top">500&#xA0;mg/day for 7&#xA0;days<hr/></td>
                <td align="left" valign="top">Mean 52.2 (range: 40&#x2013;74)<hr/></td>
                <td align="left" valign="top">Oral<hr/></td>
                <td align="left" valign="top">Clinical cure rate: 88% (within 8&#xA0;days), 100% (within 14&#xA0;days)<hr/></td>
                <td align="left" valign="top">BMD MIC*<sub>90</sub> (range): 16 (4&#x2013;32)<hr/></td>
                <td align="left" valign="top">[<xref ref-type="bibr" rid="B7">7</xref>]<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="top">Chinh, 2000<hr/></td>
                <td align="left" valign="top">Vietnam<hr/></td>
                <td align="left" valign="top">n&#x2009;=&#x2009;44, mean age (range): 26.6 (15&#x2013;68)<hr/></td>
                <td align="left" valign="top">1&#xA0;g/day for 5&#xA0;days<hr/></td>
                <td align="left" valign="top">Mean 47.3 (range: 34&#x2013;60)<hr/></td>
                <td align="left" valign="top">Oral<hr/></td>
                <td align="left" valign="top">Clinical cure rate: 95.5%<hr/></td>
                <td align="left" valign="top">E-test, MIC<sub>90</sub> (range): 8 (4&#x2013;16)<hr/></td>
                <td align="left" valign="top">[<xref ref-type="bibr" rid="B10">10</xref>]<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="top">Parry, 2007<hr/></td>
                <td align="left" valign="top">Vietnam<hr/></td>
                <td align="left" valign="top">n&#x2009;=&#x2009;62, mean age (range): 10.5 (4&#x2013;42)<hr/></td>
                <td align="left" valign="top">10&#xA0;mg/kg/day for 7&#xA0;days<hr/></td>
                <td align="left" valign="top">Mean 24 (range: 12&#x2013;58)<hr/></td>
                <td align="left" valign="top">Oral<hr/></td>
                <td align="left" valign="top">Clinical cure rate: 82%<hr/></td>
                <td align="left" valign="top">E-test MIC<sub>90</sub> (range): 16 (4&#x2013;32)<hr/></td>
                <td align="left" valign="top">[<xref ref-type="bibr" rid="B8">8</xref>]<hr/></td>
              </tr>
              <tr>
                <td align="left" valign="top">Dolecek, 2008</td>
                <td align="left" valign="top">Vietnam</td>
                <td align="left" valign="top">n&#x2009;=&#x2009;142, median age 11&#xA0;yrs, (range 1&#x2013;41)</td>
                <td align="left" valign="top">20&#xA0;mg/kg/day for 7&#xA0;days</td>
                <td align="left" valign="top">Median 24.5 (9.5&#x2013;57)</td>
                <td align="left" valign="top">Oral</td>
                <td align="left" valign="top">Treatement failure: 9.3%</td>
                <td align="left" valign="top">E-test, MIC<sub>90</sub> (range): 12 (4&#x2013;16)</td>
                <td align="left" valign="top">[<xref ref-type="bibr" rid="B11">11</xref>]</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>Abbreviations: <italic>BMD</italic> broth microdilution, <italic>MIC</italic> Minimum inhibitory concentrations, <italic>NA</italic> data not available.</p>
            <p>*MIC<sub>90</sub> were determined based on the data provided in refeneces.</p>
          </table-wrap-foot>
        </table-wrap>
        <p>In this case, no infectious focus such as arteritis or abscesses was detected by the PET-CT scan and abdominal sonography. We suspected that the thickening of intestinal wall of the colon might be due to the hypertrophy of Peyer&#x2019;s patches; one of the classic presentations observed in cases of enteric fever due to <italic>Salmonella</italic> Typhi or <italic>Salmonella</italic> Paratyphi [<xref ref-type="bibr" rid="B21">21</xref>].</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>There are limited data available for the treatment of enteric fever using azithromycin in travelers from developed countries who are not immune to the disease, and thus, careful follow-up is necessary. Additional clinical data are needed to determine the rate of success, MIC, and contributing factors for success and/or failure of azithromycin treatment for both <italic>Salmonella</italic> Typhi and <italic>Salmonella</italic> Paratyphi.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for the publication of this case report. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>TK was responsible for drafting the manuscript, and clinical management of the case. KH and YK supervised the work and helped to draft the manuscript. KM participated in the microbiological work-ups. MM, NT, SK, YF, SK, and NO were responsible for clinical management of the case. All authors have read the manuscript and accepted the final version.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/14/404/prepub">http://www.biomedcentral.com/1471-2334/14/404/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Financial support</title>
      <p>This work was partly supported by funding from the Research on Emerging and Re-emerging Infectious Diseases by the Ministry of Health, Labor, and Welfare, Japan (H24-shinkou-ippan-013).</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Crump</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Luby</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Mintz</surname>
            <given-names>ED</given-names>
          </name>
          <article-title>The global burden of typhoid fever</article-title>
          <source>Bull World Health Organ</source>
          <year>2004</year>
          <volume>82</volume>
          <fpage>346</fpage>
          <lpage>353</lpage>
          <pub-id pub-id-type="pmid">15298225</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Humphries</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>FC</given-names>
          </name>
          <name>
            <surname>Aarestrup</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Hindler</surname>
            <given-names>JA</given-names>
          </name>
          <article-title>In vitro susceptibility testing of fluoroquinolone activity against <italic>Salmonella</italic>: recent changes to CLSI standards</article-title>
          <source>Clin Infect Dis</source>
          <year>2012</year>
          <volume>55</volume>
          <fpage>1107</fpage>
          <lpage>1113</lpage>
          <pub-id pub-id-type="pmid">22752519</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Leder</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Torresi</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Libman</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Cramer</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Castelli</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Schlagenhauf</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wilder-Smith</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Keystone</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Barnett</surname>
            <given-names>ED</given-names>
          </name>
          <name>
            <surname>von Sonnenburg</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Brownstein</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>AC</given-names>
          </name>
          <name>
            <surname>Sotir</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Esposito</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Freedman</surname>
            <given-names>DO</given-names>
          </name>
          <collab>GeoSentinel Surveillance Network</collab>
          <article-title>GeoSentinel surveillance of illness in returned travelers, 2007&#x2013;2011</article-title>
          <source>Ann Intern Med</source>
          <year>2013</year>
          <volume>158</volume>
          <fpage>456</fpage>
          <lpage>468</lpage>
          <pub-id pub-id-type="pmid">23552375</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Threlfall</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>de Pinna</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Day</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lawrence</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Alternatives to ciprofloxacin use for enteric fever, United Kingdom</article-title>
          <source>Emerg Infect Dis</source>
          <year>2008</year>
          <volume>14</volume>
          <fpage>860</fpage>
          <lpage>861</lpage>
          <pub-id pub-id-type="pmid">18439388</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="book">
          <collab>Clinical and Laboratory Standards Institute</collab>
          <source>M100-23 Performance Standards for Antimicrobial Susceptibility Testing. 2013, Twenty-Third Informational Supplement</source>
          <publisher-name>Wayne, PA</publisher-name>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="other">
          <collab>The European Committee on Antimicrobial Susceptibility Testing (EUCAST)</collab>
          <article-title>Breakpoint Tables for Interpretation of MICs and Zone Diameters Version 3.1</article-title>
          <year>2013</year>
          <comment>Available at: [<ext-link ext-link-type="uri" xlink:href="http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf">http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_3.1.pdf</ext-link>]. Accessed February 12, 2014</comment>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Butler</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Sridhar</surname>
            <given-names>CB</given-names>
          </name>
          <name>
            <surname>Daga</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Pathak</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Pandit</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Khakhria</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Potkar</surname>
            <given-names>CN</given-names>
          </name>
          <name>
            <surname>Zelasky</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>RB</given-names>
          </name>
          <article-title>Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India</article-title>
          <source>J Antimicrob Chemother</source>
          <year>1999</year>
          <volume>44</volume>
          <fpage>243</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="pmid">10473232</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Parry</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>le Phuong</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Bay</surname>
            <given-names>PV</given-names>
          </name>
          <name>
            <surname>Lanh</surname>
            <given-names>MN</given-names>
          </name>
          <name>
            <surname>le Tung</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Tham</surname>
            <given-names>NT</given-names>
          </name>
          <name>
            <surname>Wain</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hien</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Farrar</surname>
            <given-names>JJ</given-names>
          </name>
          <article-title>Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2007</year>
          <volume>51</volume>
          <fpage>819</fpage>
          <lpage>825</lpage>
          <pub-id pub-id-type="pmid">17145784</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Girgis</surname>
            <given-names>NI</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Frenck</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Sultan</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Tribble</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Khakhria</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>1999</year>
          <volume>43</volume>
          <fpage>1441</fpage>
          <lpage>1444</lpage>
          <pub-id pub-id-type="pmid">10348767</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chinh</surname>
            <given-names>NT</given-names>
          </name>
          <name>
            <surname>Parry</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Ly</surname>
            <given-names>NT</given-names>
          </name>
          <name>
            <surname>Ha</surname>
            <given-names>HD</given-names>
          </name>
          <name>
            <surname>Thong</surname>
            <given-names>MX</given-names>
          </name>
          <name>
            <surname>Diep</surname>
            <given-names>TS</given-names>
          </name>
          <name>
            <surname>Wain</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>White</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Farrar</surname>
            <given-names>JJ</given-names>
          </name>
          <article-title>A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2000</year>
          <volume>44</volume>
          <issue>7</issue>
          <fpage>1855</fpage>
          <lpage>1859</lpage>
          <pub-id pub-id-type="pmid">10858343</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Dolecek</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>TP</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>NR</given-names>
          </name>
          <name>
            <surname>Le</surname>
            <given-names>TP</given-names>
          </name>
          <name>
            <surname>Ha</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Phung</surname>
            <given-names>QT</given-names>
          </name>
          <name>
            <surname>Doan</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>TB</given-names>
          </name>
          <name>
            <surname>Duong</surname>
            <given-names>TL</given-names>
          </name>
          <name>
            <surname>Luong</surname>
            <given-names>BH</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>TB</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>TA</given-names>
          </name>
          <name>
            <surname>Pham</surname>
            <given-names>ND</given-names>
          </name>
          <name>
            <surname>Mai</surname>
            <given-names>NL</given-names>
          </name>
          <name>
            <surname>Phan</surname>
            <given-names>VB</given-names>
          </name>
          <name>
            <surname>Vo</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>VM</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>TC</given-names>
          </name>
          <name>
            <surname>Schultsz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dunstan</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Stepniewska</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>JI</given-names>
          </name>
          <name>
            <surname>To</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Basnyat</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>VV</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>VS</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>TC</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Farrar</surname>
            <given-names>J</given-names>
          </name>
          <article-title>A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam</article-title>
          <source>PLoS One</source>
          <year>2008</year>
          <volume>3</volume>
          <issue>5</issue>
          <fpage>e2188</fpage>
          <pub-id pub-id-type="pmid">18493312</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bhan</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Bahl</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bhatnagar</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Typhoid and paratyphoid fever</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>366</volume>
          <fpage>749</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="pmid">16125594</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="book">
          <name>
            <surname>Longo</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Fauci</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Kasper</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Hauser</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Jameson</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Loscalzo</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Harrison&#x2019;s principles of internal medicine</article-title>
          <source>Enteric (Typhoid) Fever. Volume 2</source>
          <year>2011</year>
          <edition>18</edition>
          <publisher-name>New York: McGraw Hill</publisher-name>
          <fpage>1277</fpage>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="other">
          <name>
            <surname>Effa</surname>
            <given-names>EE</given-names>
          </name>
          <name>
            <surname>Lassi</surname>
            <given-names>ZS</given-names>
          </name>
          <name>
            <surname>Critchley</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Garner</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sinclair</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Olliaro</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>Bhutta</surname>
            <given-names>ZA</given-names>
          </name>
          <article-title>Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2011</year>
          <issue>10</issue>
          <comment>doi:10.1002/14651858.CD004530.pub4</comment>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Molloy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nair</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Cooke</surname>
            <given-names>FJ</given-names>
          </name>
          <name>
            <surname>Wain</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Farrington</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lehner</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Torok</surname>
            <given-names>ME</given-names>
          </name>
          <article-title>First report of <italic>Salmonella enterica</italic> serotype paratyphi A azithromycin resistance leading to treatment failure</article-title>
          <source>J Clin Microbiol</source>
          <year>2010</year>
          <volume>48</volume>
          <fpage>4655</fpage>
          <lpage>4657</lpage>
          <pub-id pub-id-type="pmid">20943875</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fernando</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Molland</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Gottlieb</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess caused by Salmonella enterica serotype Paratyphi A</article-title>
          <source>Pathog Glob Health</source>
          <year>2012</year>
          <volume>106</volume>
          <issue>6</issue>
          <fpage>366</fpage>
          <lpage>369</lpage>
          <pub-id pub-id-type="pmid">23182142</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Foulds</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Luke</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Teng</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Willavize</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Friedman</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Curatolo</surname>
            <given-names>WJ</given-names>
          </name>
          <article-title>The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension</article-title>
          <source>J Antimicrob Chemother</source>
          <year>1996</year>
          <volume>37</volume>
          <fpage>37</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="pmid">8818844</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Panteix</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Guillaumond</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Harf</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Desbos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sapin</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Leclercq</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Perrin-Fayolle</surname>
            <given-names>M</given-names>
          </name>
          <article-title>In-vitro concentration of azithromycin in human phagocytic cells</article-title>
          <source>J Antimicrob Chemother</source>
          <year>1993</year>
          <volume>31</volume>
          <fpage>1</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">8396080</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Capoor</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Rawat</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Nair</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hasan</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Deb</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Aggarwal</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pillai</surname>
            <given-names>P</given-names>
          </name>
          <article-title>In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant <italic>Salmonella</italic> causing enteric fever</article-title>
          <source>J Med Microbiol</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>1490</fpage>
          <lpage>1494</lpage>
          <pub-id pub-id-type="pmid">17965350</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hassing</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Goessens</surname>
            <given-names>WH</given-names>
          </name>
          <name>
            <surname>van Pelt</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Mevius</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Stricker</surname>
            <given-names>BH</given-names>
          </name>
          <name>
            <surname>Molhoek</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Verbon</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>van Genderen</surname>
            <given-names>PJ</given-names>
          </name>
          <article-title>Salmonella subtypes with increased MICs for azithromycin in travelers returned to The Netherlands</article-title>
          <source>Emerg Infect Dis</source>
          <year>2014</year>
          <volume>20</volume>
          <issue>4</issue>
          <fpage>705</fpage>
          <lpage>708</lpage>
          <pub-id pub-id-type="pmid">24655478</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kraus</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Amatya</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kimula</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Histopathology of typhoid enteritis: morphologic and immunophenotypic findings</article-title>
          <source>Mod Pathol</source>
          <year>1999</year>
          <volume>12</volume>
          <issue>10</issue>
          <fpage>949</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="pmid">10530559</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
